PL 01 - Plenary Session

3 - Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer

Monday, October 22
3:35 PM - 3:45 PM
Location: Stars at Night Ballroom

Deborah Bruner, PhD, RN, FAAN

Emory University

Disclosure:
Employment
Emory U: Professor: Employee; Emory University: Professor: Employee; NRG Oncology: NCORP PI: Independent Contractor

Compensation
Radiation Therapy Oncology Group: Research Grants, Travel Expenses

Leadership
NCAB: member; NCI Symptom Mgmt & HRQOL Comm: member; NRG Oncology: Deputy Chair, Publications; RTOG Foundation: member; RTOG Foundation Board: member

Biography:
Deborah Watkins Bruner, RN, PhD, FAAN, is Professor and Robert W. Woodruff Chair in Nursing, Professor of Radiation Oncology, Associate Director, Mentorship, Education and Training, Winship Cancer Institute, Emory University, Atlanta, GA.

She is an internationally renowned clinical trialist with a focus on patient reported outcomes, symptom management, and comparative effectiveness of radiotherapy modalities. Her current research is focused on the role of the human microbiome in carcinogenesis and cancer treatment outcomes. Her global work includes leading a project in training for 3D treatment planning and quality assurance in advance of the opening the first modern linear accelerator at in Ethiopia at Addis Ababa University.

Dr. Bruner is the only nurse to lead a national clinical trials cooperative group, first as the Principal Investigator (PI) of the Radiation Therapy Oncology Group (RTOG) Community Clinical Oncology Program (CCOP), and currently as multi-PI of the NRG Oncology group National Community Oncology Research Program (NCORP). NRG Oncology, a consortium of over 1900 institutions in the U.S. and Canada, was formed by the historic merger of The National Surgical Adjuvant Breast and Prostate (NSABP), the RTOG, and the Gynecologic Oncology Group (GOG) in 2014. NRG NCORP focuses on symptom amelioration, quality of life and comparative effectiveness trials in community settings, where most cancer care is delivered.

Recognition of her work led to her appointment by President Obama to the National Cancer Advisory Board, on which she still serves. She is a member of the National Academy of Medicine and has won numerous awards for research and mentorship.

Dr. Bruner earned her PhD at the University of Pennsylvania and has been continuously funded since 1998, culminating in her ranking among the top 5% of all NIH funded investigators in the world since 2012, according to the Blue Ridge Institute.
Follow her on Twitter @DeborahBruner1.

Presentation(s):

Send Email for Deborah Bruner


Assets

3 - Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Patient Reported Outcomes of NRG Oncology/RTOG 0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone in Intermediate Risk Prostate Cancer